Replies to post #347 on ImmunoGen Inc (IMGN)

[skitahoe]

Pay particular attention to upcoming Abstract's that will be presented at ASCO. You can find links to some of them in recent posts on I-V.

I believe the upside here is tremendous because of the pipeline, and because last year the price fell dramatically on no really bad news, but clearly IMGN 853 required a Phase 3 instead of a Registrational Phase 2. The Phase 3, and other trials are now underway, and I believe that results in a variety of combination trials are looking good. A really good year would have us above highs seen in 2015.

I'm uncertain when more will be heard from Bayer, but their drug which is in a Registrational Phase 2 should have that trial complete later this year. I believe that it could be on the market by third quarter of next year, and IMGN should see both milestones, and ultimately routinely receive royalties on sales.

Gary